Synergy Pharmaceuticals Announces Partial Exercise of Over-Allotment Option by Aegis Capital

Synergy Pharmaceuticals Inc.

, a developer of new drugs to treat gastrointestinal disorders and diseases, announced the partial exercise of the over-allotment option granted to the underwriters with respect to the purchase of 750,000 shares of common stock at a public offering price of $4.50 per share, in connection with its previously announced underwritten public offering of 10,000,000 shares of common stock, bringing total gross proceeds from the offering to $48,375,000.